KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Income (2016 - 2025)

Historic Net Income for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q3 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Net Income rose 358.71% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 86596.5%. This contributed to the annual value of -$535.6 million for FY2024, which is 11479.72% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Net Income of $1.1 billion as of Q3 2025, which was up 358.71% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Income peaked at $1.1 billion during Q1 2024, and registered a low of -$3.6 billion during Q2 2024.
  • Moreover, its 5-year median value for Net Income was $851.9 million (2021), whereas its average is $605.8 million.
  • In the last 5 years, Vertex Pharmaceuticals' Net Income soared by 110970.15% in 2022 and then tumbled by 49244.29% in 2024.
  • Vertex Pharmaceuticals' Net Income (Quarter) stood at $770.1 million in 2021, then grew by 6.34% to $818.9 million in 2022, then grew by 18.31% to $968.8 million in 2023, then dropped by 5.76% to $913.0 million in 2024, then grew by 18.61% to $1.1 billion in 2025.
  • Its Net Income stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $646.3 million for Q1 2025.